ILSI-Biomed Israel

Abbott Diagnostics @ Biomed 2011

Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas: o Evidence of clinical utility o Well characterized antibody development o Preferably, a developed ELISA format o Workable, defendable, global IP position Tweet

Startup Weekly: ProtAb – Antibodies Against Arthritis

ProtAb is a company dedicated to eveloping an antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn's Disease, and has recently raised $4 million. Name: ProtAb CEO: Shira Yair Sector: Biopharma Medical Field: Autoimmune Diseases Est.: 2005 Stage: Late stage pre-clinical, after series A funding Vision: To develop a novel therapeutics for autoimmune diseases, based on the induction of natural anti-inflammatory mechanisms existing in...

Champions Biotechnology Establishes a License with Ramot for the Development and Commercialization of a Tumor-Fixing Antibody

A new single-chain antibody fragment, identified by Tel Aviv University researchers as having the ability to fix a protein that’s mutated in more than 50 percent of human tumors, has been licensed to Champions Biotechnology for development and commercialization. Back when I was a first degree student of biology, I was sternly told that antibodies are only used for diagnostic purposes. It never struck me quite right. After all, in the body they’re an important part of the immune system. Am...